References analysis of the Wikipedia article "Rak wątrobowokomórkowy" in the Polish version

doi.org

J.M. Llovet, M. Ducreux, R. Lencioni, A.M. Di Bisceglie i inni. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. „J Hepatol”. 56 (4), s. 908–943, Apr 2012. DOI: 10.1016/j.jhep.2011.12.001. PMID: 22424438. [zarchiwizowane z adresu].

A. Reuben, R.P. Beasley. The crab, the turkey and a malignant tale from the year of the rooster. „Hepatology”. 41 (4), s. 944–950, Apr 2005. DOI: 10.1002/hep.20674. PMID: 15791605.

S.C. Cunningham, M.A. Choti, E.C. Bellavance, T.M. Pawlik. Palliation of hepatic tumors. „Surg Oncol”. 16 (4), s. 277–291, Dec 2007. DOI: 10.1016/j.suronc.2007.08.010. PMID: 17935975.

Y.S. Guan, Q. He, M.Q. Wang. Transcatheter arterial chemoembolization: history for more than 30 years. „ISRN Gastroenterol”. 2012, s. 480650, 2012. DOI: 10.5402/2012/480650. PMID: 22966466.

A. Roche, D. Franco, D. Dhumeaux, H. Bismuth i inni. Emergency hepatic arterial embolization for secondary hypercalcemia in hepatocellular carcinoma. „Radiology”. 133 (2), s. 315–316, Nov 1979. DOI: 10.1148/133.2.315. PMID: 227010.

J.M. Llovet, C. Brú, J. Bruix. Prognosis of hepatocellular carcinoma: the BCLC staging classification. „Semin Liver Dis”. 19 (3), s. 329–338, 1999. DOI: 10.1055/s-2007-1007122. PMID: 10518312.

J.M. Llovet, J. Bruix. Novel advancements in the management of hepatocellular carcinoma in 2008. „J Hepatol”. 48 Suppl 1, s. S20-37, 2008. DOI: 10.1016/j.jhep.2008.01.022. PMID: 18304676.

H.B. El-Serag. Hepatocellular carcinoma. „N Engl J Med”. 365 (12), s. 1118–1127, Sep 2011. DOI: 10.1056/NEJMra1001683. PMID: 21992124.

J.M. Llovet, A. Burroughs, J. Bruix. Hepatocellular carcinoma. „Lancet”. 362 (9399), s. 1907–1917, Dec 2003. DOI: 10.1016/S0140-6736(03)14964-1. PMID: 14667750.

H.B. El-Serag, K.L. Rudolph. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. „Gastroenterology”. 132 (7), s. 2557–2576, Jun 2007. DOI: 10.1053/j.gastro.2007.04.061. PMID: 17570226.

A.P. Venook, C. Papandreou, J. Furuse, L.L. de Guevara. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. „Oncologist”. 15 Suppl 4, s. 5–13, 2010. DOI: 10.1634/theoncologist.2010-S4-05. PMID: 21115576.

J.F. Perz, G.L. Armstrong, L.A. Farrington, Y.J. Hutin i inni. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. „J Hepatol”. 45 (4), s. 529–538, Oct 2006. DOI: 10.1016/j.jhep.2006.05.013. PMID: 16879891.

S. Caldwell, S.H. Park. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. „J Gastroenterol”. 44 Suppl 19, s. 96–101, 2009. DOI: 10.1007/s00535-008-2258-6. PMID: 19148801.

S.L. Friedman, M.J. Arthur. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. „J Clin Invest”. 84 (6), s. 1780–1785, Dec 1989. DOI: 10.1172/JCI114362. PMID: 2556445.

S.W. Jeong, J.Y. Jang, R.T. Chung. Hepatitis C virus and hepatocarcinogenesis. „Clin Mol Hepatol”. 18 (4), s. 347–356, Dec 2012. DOI: 10.3350/cmh.2012.18.4.347. PMID: 23323249.

C.M. Schmidt, I.H. McKillop, P.A. Cahill, J.V. Sitzmann. Increased MAPK expression and activity in primary human hepatocellular carcinoma. „Biochem Biophys Res Commun”. 236 (1), s. 54–58, Jul 1997. DOI: 10.1006/bbrc.1997.6840. PMID: 9223425.

Q. Zhou, V.W. Lui, W. Yeo. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. „Future Oncol”. 7 (10), s. 1149–1167, Oct 2011. DOI: 10.2217/fon.11.95. PMID: 21992728.

A. Satyanarayana, M.P. Manns, K.L. Rudolph. Telomeres and telomerase: a dual role in hepatocarcinogenesis. „Hepatology”. 40 (2), s. 276–283, Aug 2004. DOI: 10.1002/hep.20308. PMID: 15368430.

S.L. Friedman. Mechanisms of hepatic fibrogenesis. „Gastroenterology”. 134 (6), s. 1655–1669, May 2008. DOI: 10.1053/j.gastro.2008.03.003. PMID: 18471545.

Adrian M. Di Bisceglie. Hepatitis B and Hepatocellular Carcinoma. „Hepatology.”, 2009-05. DOI: 10.1002/hep.22962.

A.M. Di Bisceglie, A.C. Lyra, M. Schwartz, R.K. Reddy i inni. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. „Am J Gastroenterol”. 98 (9), s. 2060–2063, Sep 2003. DOI: 10.1111/j.1572-0241.2003.t01-1-07641.x. PMID: 14499788.

C.J. Chen, H.I. Yang, J. Su, C.L. Jen i inni. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. „JAMA”. 295 (1), s. 65–73, Jan 2006. DOI: 10.1001/jama.295.1.65. PMID: 16391218.

B. Tang, W.D. Kruger, G. Chen, F. Shen i inni. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. „J Med Virol”. 72 (1), s. 35–40, Jan 2004. DOI: 10.1002/jmv.10559. PMID: 14635008.

R. Muroyama, N. Kato, H. Yoshida, M. Otsuka i inni. Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. „J Hepatol”. 45 (6), s. 805–812, Dec 2006. DOI: 10.1016/j.jhep.2006.07.025. PMID: 17050029.

X. Ding, M. Mizokami, G. Yao, B. Xu i inni. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. „Intervirology”. 44 (1), s. 43–47, 2001. DOI: 10.1159/000050029. PMID: 11223719.

Luis Jesuino de Oliveria Andrade, Argemiro D’Oliveira, Junior, Rosangela Carvalho Melo, Emmanuel Conrado De Souza, Carolina Alves Costa Silva, Raymundo Paraná. Association Between Hepatitis C and Hepatocellular Carcinoma. „J Glob Infect Dis”, 2009. DOI: 10.4103/0974-777X.52979.

H.B. El-Serag. Hepatocellular carcinoma and hepatitis C in the United States. „Hepatology”. 36 (5 Suppl 1), s. S74-83, Nov 2002. DOI: 10.1053/jhep.2002.36807. PMID: 12407579.

K. Koike. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. „J Gastroenterol Hepatol”. 22 Suppl 1, s. S108-11, Jun 2007. DOI: 10.1111/j.1440-1746.2006.04669.x. PMID: 17567457.

T.Y. Leong, A.S. Leong. Epidemiology and carcinogenesis of hepatocellular carcinoma. „HPB (Oxford)”. 7 (1), s. 5–15, 2005. DOI: 10.1080/13651820410024021. PMID: 18333156.

K. Koike. The oncogenic role of hepatitis C virus. „Recent Results Cancer Res”. 193, s. 97–111, 2014. DOI: 10.1007/978-3-642-38965-8_6. PMID: 24008295.

K. Moriya, H. Fujie, Y. Shintani, H. Yotsuyanagi i inni. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. „Nat Med”. 4 (9), s. 1065–1067, Sep 1998. DOI: 10.1038/2053. PMID: 9734402.

A. Alisi, S. Giambartolomei, F. Cupelli, P. Merlo i inni. Physical and functional interaction between HCV core protein and the different p73 isoforms. „Oncogene”. 22 (17), s. 2573–2580, May 2003. DOI: 10.1038/sj.onc.1206333. PMID: 12730672.

T. Yamanaka, T. Kodama, T. Doi. Subcellular localization of HCV core protein regulates its ability for p53 activation and p21 suppression. „Biochem Biophys Res Commun”. 294 (3), s. 528–534, Jun 2002. DOI: 10.1016/S0006-291X(02)00508-9. PMID: 12056798.

T. Tsutsumi, T. Suzuki, K. Moriya, Y. Shintani i inni. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. „Hepatology”. 38 (4), s. 820–828, Oct 2003. DOI: 10.1053/jhep.2003.50399. PMID: 14512869.

M. Levrero. Viral hepatitis and liver cancer: the case of hepatitis C. „Oncogene”. 25 (27), s. 3834–3847, Jun 2006. DOI: 10.1038/sj.onc.1209562. PMID: 16799625.

W.L. Tsai, R.T. Chung. Viral hepatocarcinogenesis. „Oncogene”. 29 (16), s. 2309–2324, Apr 2010. DOI: 10.1038/onc.2010.36. PMID: 20228847.

R. Romeo, B. Foglieni, G. Casazza, M. Spreafico i inni. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. „PLoS One”. 9 (3), s. e92062, 2014. DOI: 10.1371/journal.pone.0092062. PMID: 24658127.

M.B. Thomas, A.X. Zhu. Hepatocellular carcinoma: the need for progress. „J Clin Oncol”. 23 (13), s. 2892–2899, May 2005. DOI: 10.1200/JCO.2005.03.196. PMID: 15860847.

M. Frezza, C. di Padova, G. Pozzato, M. Terpin i inni. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. „N Engl J Med”. 322 (2), s. 95–99, Jan 1990. DOI: 10.1056/NEJM199001113220205. PMID: 2248624.

D.M. Torres, S.A. Harrison. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. „Semin Liver Dis”. 32 (1), s. 30–38, Feb 2012. DOI: 10.1055/s-0032-1306424. PMID: 22418886.

J.M. Clark, A.M. Diehl. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. „JAMA”. 289 (22), s. 3000–3004, Jun 2003. DOI: 10.1001/jama.289.22.3000. PMID: 12799409.

M.S. Ascha, I.A. Hanouneh, R. Lopez, T.A. Tamimi i inni. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. „Hepatology”. 51 (6), s. 1972–1978, Jun 2010. DOI: 10.1002/hep.23527. PMID: 20209604.

S. Kojima, N. Watanabe, M. Numata, T. Ogawa i inni. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. „J Gastroenterol”. 38 (10), s. 954–961, 2003. DOI: 10.1007/s00535-003-1178-8. PMID: 14614602.

L. Kikuchi, C.P. Oliveira, F.J. Carrilho. Nonalcoholic fatty liver disease and hepatocellular carcinoma. „Biomed Res Int”. 2014, s. 106247, 2014. DOI: 10.1155/2014/106247. PMID: 24738043.

J.A. Price, S.J. Kovach, T. Johnson, L.G. Koniaris i inni. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. „Hepatology”. 36 (5), s. 1089–1097, Nov 2002. DOI: 10.1053/jhep.2002.36158. PMID: 12395318.

S. Yang, H. Zhu, Y. Li, H. Lin i inni. Mitochondrial adaptations to obesity-related oxidant stress. „Arch Biochem Biophys”. 378 (2), s. 259–268, Jun 2000. DOI: 10.1006/abbi.2000.1829. PMID: 10860543.

M. Kitade, H. Yoshiji, H. Kojima, Y. Ikenaka i inni. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. „Hepatology”. 44 (4), s. 983–991, Oct 2006. DOI: 10.1002/hep.21338. PMID: 17006938.

S. Nair, A. Mason, J. Eason, G. Loss i inni. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. „Hepatology”. 36 (1), s. 150–155, Jul 2002. DOI: 10.1053/jhep.2002.33713. PMID: 12085359.

J.A. Davila, R.O. Morgan, Y. Shaib, K.A. McGlynn i inni. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. „Gut”. 54 (4), s. 533–539, Apr 2005. DOI: 10.1136/gut.2004.052167. PMID: 15753540.

A.L. Mason, J.Y. Lau, N. Hoang, K. Qian i inni. Association of diabetes mellitus and chronic hepatitis C virus infection. „Hepatology”. 29 (2), s. 328–333, Feb 1999. DOI: 10.1002/hep.510290235. PMID: 9918906.

H.C. Wu, Q. Wang, H.I. Yang, H. Ahsan i inni. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. „Cancer Epidemiol Biomarkers Prev”. 18 (3), s. 846–853, Mar 2009. DOI: 10.1158/1055-9965.EPI-08-0697. PMID: 19273485.

A. Magnussen, M.A. Parsi. Aflatoxins, hepatocellular carcinoma and public health. „World J Gastroenterol”. 19 (10), s. 1508–1512, Mar 2013. DOI: 10.3748/wjg.v19.i10.1508. PMID: 23539499.

H.C. Wu, R. Santella. The role of aflatoxins in hepatocellular carcinoma. „Hepat Mon”. 12 (10 HCC), s. e7238, Oct 2012. DOI: 10.5812/hepatmon.7238. PMID: 23162603.

C.P. Wild, Y.Y. Gong. Mycotoxins and human disease: a largely ignored global health issue. „Carcinogenesis”. 31 (1), s. 71–82, Jan 2010. DOI: 10.1093/carcin/bgp264. PMID: 19875698.

J.D. Groopman, T.W. Kensler, C.P. Wild. Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. „Annu Rev Public Health”. 29, s. 187–203, 2008. DOI: 10.1146/annurev.publhealth.29.020907.090859. PMID: 17914931.

Y. Liu, F. Wu. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. „Environ Health Perspect”. 118 (6), s. 818–824, Jun 2010. DOI: 10.1289/ehp.0901388. PMID: 20172840.

G.D. Kirk, E. Bah, R. Montesano. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. „Carcinogenesis”. 27 (10), s. 2070–2082, Oct 2006. DOI: 10.1093/carcin/bgl060. PMID: 16679307.

S.Y. Kuang, S. Lekawanvijit, N. Maneekarn, S. Thongsawat i inni. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. „Cancer Epidemiol Biomarkers Prev”. 14 (2), s. 380–384, Feb 2005. DOI: 10.1158/1055-9965.EPI-04-0380. PMID: 15734961.

M.C. Kew. Hepatic iron overload and hepatocellular carcinoma. „Liver Cancer”. 3 (1), s. 31–40, Mar 2014. DOI: 10.1159/000343856. PMID: 24804175.

D.A. Rudnick, D.H. Perlmutter. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. „Hepatology”. 42 (3), s. 514–521, Sep 2005. DOI: 10.1002/hep.20815. PMID: 16044402.

T.A. Dragani. Risk of HCC: genetic heterogeneity and complex genetics. „J Hepatol”. 52 (2), s. 252–257, Feb 2010. DOI: 10.1016/j.jhep.2009.11.015. PMID: 20022654.

C.R. Scott. The genetic tyrosinemias. „Am J Med Genet C Semin Med Genet”. 142C (2), s. 121–126, May 2006. DOI: 10.1002/ajmg.c.30092. PMID: 16602095.

P.J. Lee. Glycogen storage disease type I: pathophysiology of liver adenomas. „Eur J Pediatr”. 161 Suppl 1, s. S46-9, Oct 2002. DOI: 10.1007/s00431-002-1002-0. PMID: 12373570.

L.M. Franco, V. Krishnamurthy, D. Bali, D.A. Weinstein i inni. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. „J Inherit Metab Dis”. 28 (2), s. 153–162, 2005. DOI: 10.1007/s10545-005-7500-2. PMID: 15877204.

M.A. Hamed, S.A. Ali. Non-viral factors contributing to hepatocellular carcinoma. „World J Hepatol”. 5 (6), s. 311–322, Jun 2013. DOI: 10.4254/wjh.v5.i6.311. PMID: 23805355.

S. Maheshwari, A. Sarraj, J. Kramer, H.B. El-Serag. Oral contraception and the risk of hepatocellular carcinoma. „J Hepatol”. 47 (4), s. 506–513, Oct 2007. DOI: 10.1016/j.jhep.2007.03.015. PMID: 17462781.

J.A. Marrero, R.J. Fontana, S. Fu, H.S. Conjeevaram i inni. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. „J Hepatol”. 42 (2), s. 218–224, Feb 2005. DOI: 10.1016/j.jhep.2004.10.005. PMID: 15664247.

Y.H. Yun, K.W. Jung, J.M. Bae, J.S. Lee i inni. Cigarette smoking and cancer incidence risk in adult men: National Health Insurance Corporation Study. „Cancer Detect Prev”. 29 (1), s. 15–24, 2005. DOI: 10.1016/j.cdp.2004.08.006. PMID: 15734213.

M. Munaka, K. Kohshi, T. Kawamoto, S. Takasawa i inni. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. „J Cancer Res Clin Oncol”. 129 (6), s. 355–360, Jun 2003. DOI: 10.1007/s00432-003-0439-5. PMID: 12759747.

S.H. Jee, H. Ohrr, J.W. Sull, J.M. Samet. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. „J Natl Cancer Inst”. 96 (24), s. 1851–1856, Dec 2004. DOI: 10.1093/jnci/djh334. PMID: 15601641.

Y. Liang, Z. Yang, R. Zhong. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. „Hepatology”. 56 (4), s. 1409–1417, Oct 2012. DOI: 10.1002/hep.25788. PMID: 22504852.

K. Harada, J. Hirohara, Y. Ueno, T. Nakano i inni. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. „Hepatology”. 57 (5), s. 1942–1949, May 2013. DOI: 10.1002/hep.26176. PMID: 23197466.

F. Turati, V. Edefonti, R. Talamini, M. Ferraroni i inni. Family history of liver cancer and hepatocellular carcinoma. „Hepatology”. 55 (5), s. 1416–1425, May 2012. DOI: 10.1002/hep.24794. PMID: 22095619.

M.M. Hassan, M.R. Spitz, M.B. Thomas, S.A. Curley i inni. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. „J Hepatol”. 50 (2), s. 334–341, Feb 2009. DOI: 10.1016/j.jhep.2008.08.016. PMID: 19070394.

K.K. Tanabe, A. Lemoine, D.M. Finkelstein, H. Kawasaki i inni. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. „JAMA”. 299 (1), s. 53–60, Jan 2008. DOI: 10.1001/jama.2007.65. PMID: 18167406.

M.H. Chang, C.J. Chen, M.S. Lai, H.M. Hsu i inni. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. „N Engl J Med”. 336 (26), s. 1855–1859, Jun 1997. DOI: 10.1056/NEJM199706263362602. PMID: 9197213.

M.C. Kew. Prevention of hepatocellular carcinoma. „HPB (Oxford)”. 7 (1), s. 16–25, 2005. DOI: 10.1080/13651820410024030. PMID: 18333157.

C. Vandelli, F. Renzo, L. Romanò, S. Tisminetzky i inni. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. „Am J Gastroenterol”. 99 (5), s. 855–859, May 2004. DOI: 10.1111/j.1572-0241.2004.04150.x. PMID: 15128350.

N.A. Terrault, J.L. Dodge, E.L. Murphy, J.E. Tavis i inni. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. „Hepatology”. 57 (3), s. 881–889, Mar 2013. DOI: 10.1002/hep.26164. PMID: 23175457.

K.M. Roy, D.J. Goldberg, S. Hutchinson, S.O. Cameron i inni. Hepatitis C virus among self declared non-injecting sexual partners of injecting drug users. „J Med Virol”. 74 (1), s. 62–66, Sep 2004. DOI: 10.1002/jmv.20146. PMID: 15258969.

R.D. Kouyos, A. Rauch, D.L. Braun, W.L. Yang i inni. Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. „J Infect Dis”, Jun 2014. DOI: 10.1093/infdis/jiu315. PMID: 24943723.

A.T. Urbanus, T.J. Van De Laar, R. Geskus, J.W. Vanhommerig i inni. Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995–2010. „AIDS”. 28 (5), s. 781–790, Mar 2014. DOI: 10.1097/QAD.0000000000000126. PMID: 24832014.

T.C. Martin, N.K. Martin, M. Hickman, P. Vickerman i inni. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. „AIDS”. 27 (16), s. 2551–2557, Oct 2013. DOI: 10.1097/QAD.0b013e32836381cc. PMID: 23736152.

P.E. Chang, W.C. Ong, H.F. Lui, C.K. Tan. Epidemiology and prognosis of paraneoplastic syndromes in hepatocellular carcinoma. „ISRN Oncol”. 2013, s. 684026, 2013. DOI: 10.1155/2013/684026. PMID: 24396608.

P. Tudela, B. Soldevila, J.M. Mòdol, E. Domènech. Hypercalcemic encephalopathy in a patient with hepatocellular carcinoma. „Dig Dis Sci”. 52 (11), s. 3296–3297, Nov 2007. DOI: 10.1007/s10620-006-9159-4. PMID: 17429730.

P.E. Chang, C.K. Tan. Paraneoplastic erythrocytosis as a primary presentation of hepatocellular carcinoma. „Indian J Med Sci”. 63 (5), s. 202–203, May 2009. DOI: 10.4103/0019-5359.53167. PMID: 19584492.

K. Okushin, Y. Asaoka, I. Fukuda, N. Fujiwara i inni. IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal. „Case Rep Gastroenterol”. 6 (3), s. 784–789, Sep 2012. DOI: 10.1159/000346462. PMID: 23341802.

V. Jha, P. Borpujari. Hypoglycaemia presenting as sole manifestation of hepatocellular carcinoma. „Med J Armed Forces India”. 68 (1), s. 75–77, Jan 2012. DOI: 10.1016/S0377-1237(11)60113-5. PMID: 24669040.

M. Sorlini, F. Benini, P. Cravarezza, G. Romanelli. Hypoglycemia, an atypical early sign of hepatocellular carcinoma. „J Gastrointest Cancer”. 41 (3), s. 209–211, Sep 2010. DOI: 10.1007/s12029-010-9137-0. PMID: 20204540.

H. Yokokura, T. Demitsu, M. Kakurai, N. Umemoto i inni. Paraneoplastic pemphigus mimicking erosive mucosal lichen planus associated with primary hepatocellular carcinoma. „J Dermatol”. 33 (12), s. 842–845, Dec 2006. DOI: 10.1111/j.1346-8138.2006.00192.x. PMID: 17169086.

R. Tekaya, K. Abdelghni, L. Abdelmoula, C. Ben Hadj Yahia i inni. Hepatocellular carcinoma with polymyositis as an initial symptom: a case report. „Acta Clin Belg”. 66 (1). s. 53–54. DOI: 10.1179/ACB.66.1.2062515. PMID: 21485765.

D. Kishore, V. Khurana, A. Raj, I.S. Gambhir i inni. Hepatocellular carcinoma presenting as polymyositis: a paraneoplastic syndrome. „Ann Saudi Med”. 31 (5). s. 533–535. DOI: 10.4103/0256-4947.84636. PMID: 21911994.

S.Y. Yang, B.K. Cha, G. Kim, H.W. Lee i inni. Dermatomyositis associated with hepatitis B virus-related hepatocellular carcinoma. „Korean J Intern Med”. 29 (2), s. 231–235, Mar 2014. DOI: 10.3904/kjim.2014.29.2.231. PMID: 24648807.

L. Apostolidis, C. Kahlert, A. Siegmund, R. Thom i inni. Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib. „Onkologie”. 32 (1–2), s. 50–53, Feb 2009. DOI: 10.1159/000183750. PMID: 19209021.

P. Fasani, A. Sangiovanni, C. De Fazio, M. Borzio i inni. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. „Hepatology”. 29 (6), s. 1704–1707, Jun 1999. DOI: 10.1002/hep.510290604. PMID: 10347111.

D. Santini, F. Pantano, F. Riccardi, G.G. Di Costanzo i inni. Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. „PLoS One”. 9 (8), s. e105268, 2014. DOI: 10.1371/journal.pone.0105268. PMID: 25170882.

M. Kanda, R. Tateishi, H. Yoshida, T. Sato i inni. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. „Liver Int”. 28 (9), s. 1256–1263, Nov 2008. DOI: 10.1111/j.1478-3231.2008.01864.x. PMID: 18710423.

A.N. Elzouki, H. Elkhider, K. Yacout, A. Al Muzrakchi i inni. Metastatic hepatocellular carcinoma to parotid glands. „Am J Case Rep”. 15, s. 343–347, 2014. DOI: 10.12659/AJCR.890661. PMID: 25129420.

L. Bolondi, S. Gaiani, N. Celli, R. Golfieri i inni. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. „Hepatology”. 42 (1), s. 27–34, Jul 2005. DOI: 10.1002/hep.20728. PMID: 15954118.

T. Roskams, M. Kojiro. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. „Semin Liver Dis”. 30 (1), s. 17–25, Feb 2010. DOI: 10.1055/s-0030-1247129. PMID: 20175030.

J. Bruix, M. Sherman. Management of hepatocellular carcinoma. „Hepatology”. 42 (5), s. 1208–1236, Nov 2005. DOI: 10.1002/hep.20933. PMID: 16250051.

A. Forner, R. Vilana, C. Ayuso, L. Bianchi i inni. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. „Hepatology”. 47 (1), s. 97–104, Jan 2008. DOI: 10.1002/hep.21966. PMID: 18069697.

A. Sangiovanni, M.A. Manini, M. Iavarone, R. Romeo i inni. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. „Gut”. 59 (5), s. 638–644, May 2010. DOI: 10.1136/gut.2009.187286. PMID: 19951909.

J. Bruix, M. Sherman. Management of hepatocellular carcinoma: an update. „Hepatology”. 53 (3), s. 1020–1022, Mar 2011. DOI: 10.1002/hep.24199. PMID: 21374666.

T. Hennedige, S.K. Venkatesh. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. „Cancer Imaging”. 12, s. 530–547, 2013. DOI: 10.1102/1470-7330.2012.0044. PMID: 23400006.

E.S. Bialecki, A.M. Di Bisceglie. Diagnosis of hepatocellular carcinoma. „HPB (Oxford)”. 7 (1), s. 26–34, 2005. DOI: 10.1080/13651820410024049. PMID: 18333158.

A. Kircher, G. Bongartz, E.M. Merkle, C.J. Zech. [Rational imaging of hepatocellular carcinoma. The challenge of multimodal diagnostic criteria]. „Radiologe”. 54 (7), s. 664–672, Jul 2014. DOI: 10.1007/s00117-014-2652-4. PMID: 25047522.

H.Y. Chen, Y.L. Hou, X.M. Ma, H.Y. Xie i inni. CT and MRI in target delineation in primary hepatocellular carcinoma. „Cancer Radiother”. 17 (8), s. 750–754, Dec 2013. DOI: 10.1016/j.canrad.2013.05.016. PMID: 24262499.

O. Matsui, M. Kadoya, T. Kameyama, J. Yoshikawa i inni. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. „Radiology”. 178 (2), s. 493–497, Feb 1991. DOI: 10.1148/radiology.178.2.1846240. PMID: 1846240.

R.L. Baron, J.H. Oliver, G.D. Dodd, M. Nalesnik i inni. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. „Radiology”. 199 (2), s. 505–511, May 1996. DOI: 10.1148/radiology.199.2.8668803. PMID: 8668803.

J. Ward, P.J. Robinson. How to detect hepatocellular carcinoma in cirrhosis. „Eur Radiol”. 12 (9), s. 2258–2272, Sep 2002. DOI: 10.1007/s00330-002-1450-y. PMID: 12195479.

A. Laghi, R. Iannaccone, P. Rossi, I. Carbone i inni. Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. „Radiology”. 226 (2), s. 543–549, Feb 2003. DOI: 10.1148/radiol.2262012043. PMID: 12563152.

M. Ebara, H. Fukuda, Y. Kojima, N. Morimoto i inni. Small hepatocellular carcinoma: relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchyma. „Radiology”. 210 (1), s. 81–88, Jan 1999. DOI: 10.1148/radiology.210.1.r99ja4181. PMID: 9885591.

Z. Zheng, W. Liang, D.P. Milgrom, Z. Zheng i inni. Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies. „Transplantation”. 97 (2), s. 227–234, Jan 2014. DOI: 10.1097/TP.0b013e3182a89383. PMID: 24142034.

T. Nishiharu, Y. Yamashita, A. Arakawa, S. Sumi i inni. Sonographic comparison of intraarterial CO2 and helium microbubbles for detection of hepatocellular carcinoma: preliminary observations. „Radiology”. 206 (3), s. 767–771, Mar 1998. DOI: 10.1148/radiology.206.3.9494499. PMID: 9494499.

S.W. Ryu, G.H. Bok, J.Y. Jang, S.W. Jeong i inni. Clinically useful diagnostic tool of contrast enhanced ultrasonography for focal liver masses: comparison to computed tomography and magnetic resonance imaging. „Gut Liver”. 8 (3), s. 292–297, May 2014. DOI: 10.5009/gnl.2014.8.3.292. PMID: 24827626.

C. Reinhold, L. Hammers, C.R. Taylor, C.L. Quedens-Case i inni. Characterization of focal hepatic lesions with duplex sonography: findings in 198 patients. „AJR Am J Roentgenol”. 164 (5), s. 1131–1135, May 1995. DOI: 10.2214/ajr.164.5.7717219. PMID: 7717219.

S. Tanaka, T. Kitamura, M. Fujita, K. Nakanishi i inni. Color Doppler flow imaging of liver tumors. „AJR Am J Roentgenol”. 154 (3), s. 509–514, Mar 1990. DOI: 10.2214/ajr.154.3.2154912. PMID: 2154912.

S.G. Zheng, H.X. Xu, L.N. Liu. Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound. „World J Radiol”. 6 (1), s. 7–14, Jan 2014. DOI: 10.4329/wjr.v6.i1.7. PMID: 24578787.

K.H. Hwang, D.J. Choi, S.Y. Lee, M.K. Lee i inni. Evaluation of patients with hepatocellular carcinomas using [(11)C]acetate and [(18)F]FDG PET/CT: A preliminary study. „Appl Radiat Isot”. 67 (7–8). s. 1195–1198. DOI: 10.1016/j.apradiso.2009.02.011. PMID: 19342249.

N. Salem, Y. Kuang, D. Corn, B. Erokwu i inni. [(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma. „Mol Imaging Biol”. 13 (1), s. 140–151, Feb 2011. DOI: 10.1007/s11307-010-0308-y. PMID: 20401538.

J.N. Talbot, L. Fartoux, S. Balogova, V. Nataf i inni. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. „J Nucl Med”. 51 (11), s. 1699–1706, Nov 2010. DOI: 10.2967/jnumed.110.075507. PMID: 20956466.

F. Durand, J. Belghiti, V. Paradis. Liver transplantation for hepatocellular carcinoma: role of biopsy. „Liver Transpl”. 13 (11 Suppl 2), s. S17-23, Nov 2007. DOI: 10.1002/lt.21326. PMID: 17969095.

M. Kojiro, I.R. Wanless, V. Alves, S. Badve i inni. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. „Hepatology”. 49 (2), s. 658–664, Feb 2009. DOI: 10.1002/hep.22709. PMID: 19177576.

M.A. Silva, B. Hegab, C. Hyde, B. Guo i inni. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. „Gut”. 57 (11), s. 1592–1596, Nov 2008. DOI: 10.1136/gut.2008.149062. PMID: 18669577.

Y.J. Zhao, Q. Ju, G.C. Li. Tumor markers for hepatocellular carcinoma. „Mol Clin Oncol”. 1 (4), s. 593–598, Jul 2013. DOI: 10.3892/mco.2013.119. PMID: 24649215.

E.N. Debruyne, J.R. Delanghe. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. „Clin Chim Acta”. 395 (1–2), s. 19–26, Sep 2008. DOI: 10.1016/j.cca.2008.05.010. PMID: 18538135.

A. Singal, M.L. Volk, A. Waljee, R. Salgia i inni. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. „Aliment Pharmacol Ther”. 30 (1), s. 37–47, Jul 2009. DOI: 10.1111/j.1365-2036.2009.04014.x. PMID: 19392863.

M. Kobayashi, T. Hosaka, K. Ikeda, Y. Seko i inni. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. „Hepatol Res”. 41 (11), s. 1036–1045, Nov 2011. DOI: 10.1111/j.1872-034X.2011.00858.x. PMID: 21883741.

A. Singhal, M. Jayaraman, D.N. Dhanasekaran, V. Kohli. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. „Crit Rev Oncol Hematol”. 82 (2), s. 116–140, May 2012. DOI: 10.1016/j.critrevonc.2011.05.005. PMID: 21680198.

A. Leerapun, S.V. Suravarapu, J.P. Bida, R.J. Clark i inni. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. „Clin Gastroenterol Hepatol”. 5 (3), s. 394-402; quiz 267, Mar 2007. DOI: 10.1016/j.cgh.2006.12.005. PMID: 17368240.

M. Guido, T. Roskams, P. Pontisso, M. Fassan i inni. Squamous cell carcinoma antigen in human liver carcinogenesis. „J Clin Pathol”. 61 (4), s. 445–447, Apr 2008. DOI: 10.1136/jcp.2007.051383. PMID: 17893121.

G. Giannelli, F. Marinosci, C. Sgarra, L. Lupo i inni. Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma. „Int J Cancer”. 116 (4), s. 579–583, Sep 2005. DOI: 10.1002/ijc.20847. PMID: 15825162.

J. Filmus, M. Capurro, J. Rast. Glypicans. „Genome Biol”. 9 (5), s. 224, 2008. DOI: 10.1186/gb-2008-9-5-224. PMID: 18505598.

F. Zhang, Y. Gu, X. Li, W. Wang i inni. Up-regulated Golgi phosphoprotein 2 (GOLPH2) expression in lung adenocarcinoma tissue. „Clin Biochem”. 43 (12), s. 983–991, Aug 2010. DOI: 10.1016/j.clinbiochem.2010.05.010. PMID: 20501332.

F.R. Fritzsche, G. Kristiansen, M.O. Riener, M. Dietel i inni. GOLPH2 expression may serve as diagnostic marker in seminomas. „BMC Urol”. 10, s. 4, 2010. DOI: 10.1186/1471-2490-10-4. PMID: 20184749.

F.R. Fritzsche, M.O. Riener, M. Dietel, H. Moch i inni. GOLPH2 expression in renal cell cancer. „BMC Urol”. 8, s. 15, 2008. DOI: 10.1186/1471-2490-8-15. PMID: 19014428.

L. Tian, Y. Wang, D. Xu, J. Gui i inni. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. „Int J Cancer”. 129 (8), s. 1923–1931, Oct 2011. DOI: 10.1002/ijc.25838. PMID: 21140449.

Y. Zhang, Z.S. Deng, M.M. Liao, N. Wang i inni. Tumor associated glycoprotein-72 is a novel marker for poor survival in hepatocellular carcinoma. „Pathol Oncol Res”. 18 (4), s. 911–916, Oct 2012. DOI: 10.1007/s12253-012-9521-0. PMID: 22434316.

D.E. Milenic, E.D. Brady, K. Garmestani, P.S. Albert i inni. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. „Cancer”. 116 (4 Suppl), s. 1059–1066, Feb 2010. DOI: 10.1002/cncr.24793. PMID: 20127951.

V. Cartier, C. Aubé. Diagnosis of hepatocellular carcinoma. „Diagn Interv Imaging”. 95 (7–8). s. 709–719. DOI: 10.1016/j.diii.2014.06.004. PMID: 24997859.

A. Cucchetti, F. Piscaglia, E. Caturelli, L. Benvegnù i inni. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. „Ann Surg Oncol”. 16 (2), s. 413–422, Feb 2009. DOI: 10.1245/s10434-008-0232-4. PMID: 19034578.

S. Arii, S. Tanaka, Y. Mitsunori, N. Nakamura i inni. Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography. „Oncology”. 78 Suppl 1, s. 125–130, Jul 2010. DOI: 10.1159/000315240. PMID: 20616594.

M. Shi, R.P. Guo, X.J. Lin, Y.Q. Zhang i inni. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. „Ann Surg”. 245 (1), s. 36–43, Jan 2007. DOI: 10.1097/01.sla.0000231758.07868.71. PMID: 17197963.

T. Ishizawa, K. Hasegawa, T. Aoki, M. Takahashi i inni. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. „Gastroenterology”. 134 (7), s. 1908–1916, Jun 2008. DOI: 10.1053/j.gastro.2008.02.091. PMID: 18549877.

M. Makuuchi, K. Sano. The surgical approach to HCC: our progress and results in Japan. „Liver Transpl”. 10 (2 Suppl 1), s. S46-52, Feb 2004. DOI: 10.1002/lt.20044. PMID: 14762839.

Y. Miyake, A. Takaki, Y. Iwasaki, K. Yamamoto. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. „J Viral Hepat”. 17 (4), s. 287–292, Apr 2010. DOI: 10.1111/j.1365-2893.2009.01181.x. PMID: 19732321.

Y.C. Shen, C. Hsu, L.T. Chen, C.C. Cheng i inni. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. „J Hepatol”. 52 (6), s. 889–894, Jun 2010. DOI: 10.1016/j.jhep.2009.12.041. PMID: 20395009.

V. Mazzaferro, R. Romito, M. Schiavo, L. Mariani i inni. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. „Hepatology”. 44 (6), s. 1543–1554, Dec 2006. DOI: 10.1002/hep.21415. PMID: 17133492.

V. Mazzaferro, E. Regalia, R. Doci, S. Andreola i inni. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. „N Engl J Med”. 334 (11), s. 693–699, Mar 1996. DOI: 10.1056/NEJM199603143341104. PMID: 8594428.

A. Liccioni, M. Reig, J. Bruix. Treatment of hepatocellular carcinoma. „Dig Dis”. 32 (5), s. 554–563, 2014. DOI: 10.1159/000360501. PMID: 25034288.

S. Jonas, W.O. Bechstein, T. Steinmüller, M. Herrmann i inni. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. „Hepatology”. 33 (5), s. 1080–1086, May 2001. DOI: 10.1053/jhep.2001.23561. PMID: 11343235.

S.A. Farkas, H.J. Schlitt. [Operative therapy of hepatocellular carcinoma]. „Radiologe”. 54 (7), s. 673–678, Jul 2014. DOI: 10.1007/s00117-014-2653-3. PMID: 25047523.

M.E. Facciuto, M.K. Singh, N. Lubezky, M.A. Selim i inni. Tumors With Intrahepatic Bile Duct Differentiation in Cirrhosis: Implications on Outcomes After Liver Transplantation. „Transplantation”, Jul 2014. DOI: 10.1097/TP.0000000000000286. PMID: 25029385.

R. Ramanathan, A. Sharma, D.D. Lee, M. Behnke i inni. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. „Transplantation”. 98 (1), s. 100–106, Jul 2014. DOI: 10.1097/01.TP.0000441090.39840.b0. PMID: 24503764.

V. Mazzaferro, S. Bhoori, C. Sposito, M. Bongini i inni. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. „Liver Transpl”. 17 Suppl 2, s. S44-57, Oct 2011. DOI: 10.1002/lt.22365. PMID: 21695773.

J.M. Llovet, J. Fuster, J. Bruix. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. „Hepatology”. 30 (6), s. 1434–1440, Dec 1999. DOI: 10.1002/hep.510300629. PMID: 10573522.

H. Bismuth, P.E. Majno, R. Adam. Liver transplantation for hepatocellular carcinoma. „Semin Liver Dis”. 19 (3), s. 311–322, 1999. DOI: 10.1055/s-2007-1007120. PMID: 10518310.

P.M. Porrett, H. Peterman, M. Rosen, S. Sonnad i inni. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. „Liver Transpl”. 12 (4), s. 665–673, Apr 2006. DOI: 10.1002/lt.20636. PMID: 16482577.

A.E. Truesdale, S.H. Caldwell, N.L. Shah, C.K. Argo i inni. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. „Transpl Int”. 24 (10), s. 991–998, Oct 2011. DOI: 10.1111/j.1432-2277.2011.01299.x. PMID: 21777298.

J.W. Cheng, Y. Lv. New progress of non-surgical treatments for hepatocellular carcinoma. „Med Oncol”. 30 (1), s. 381, Mar 2013. DOI: 10.1007/s12032-012-0381-y. PMID: 23292867.

P.J. Johnson. Non-surgical treatment of hepatocellular carcinoma. „HPB (Oxford)”. 7 (1), s. 50–55, 2005. DOI: 10.1080/13651820410024076. PMID: 18333161.

R. Lencioni, L. Crocetti. Local-regional treatment of hepatocellular carcinoma. „Radiology”. 262 (1), s. 43–58, Jan 2012. DOI: 10.1148/radiol.11110144. PMID: 22190656.

M. Sala, J.M. Llovet, R. Vilana, L. Bianchi i inni. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. „Hepatology”. 40 (6), s. 1352–1360, Dec 2004. DOI: 10.1002/hep.20465. PMID: 15565564.

T. Livraghi, A. Giorgio, G. Marin, A. Salmi i inni. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. „Radiology”. 197 (1), s. 101–108, Oct 1995. DOI: 10.1148/radiology.197.1.7568806. PMID: 7568806.

R.A. Lencioni, H.P. Allgaier, D. Cioni, M. Olschewski i inni. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. „Radiology”. 228 (1), s. 235–240, Jul 2003. DOI: 10.1148/radiol.2281020718. PMID: 12759473.

T. Livraghi, S.N. Goldberg, S. Lazzaroni, F. Meloni i inni. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. „Radiology”. 210 (3), s. 655–661, Mar 1999. DOI: 10.1148/radiology.210.3.r99fe40655. PMID: 10207464.

T. Livraghi, F. Meloni, M. Di Stasi, E. Rolle i inni. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?. „Hepatology”. 47 (1), s. 82–89, Jan 2008. DOI: 10.1002/hep.21933. PMID: 18008357.

V.P. Chuang, S. Wallace, C.S. Soo, C. Charnsangavej i inni. Therapeutic Ivalon embolization of hepatic tumors. „AJR Am J Roentgenol”. 138 (2), s. 289–294, Feb 1982. DOI: 10.2214/ajr.138.2.289. PMID: 6976733.

J.M. Llovet, J. Bruix. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. „Hepatology”. 37 (2), s. 429–442, Feb 2003. DOI: 10.1053/jhep.2003.50047. PMID: 12540794.

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire. „N Engl J Med”. 332 (19), s. 1256–1261, May 1995. DOI: 10.1056/NEJM199505113321903. PMID: 7708069.

J.L. Raoul, B. Sangro, A. Forner, V. Mazzaferro i inni. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. „Cancer Treat Rev”. 37 (3), s. 212–220, May 2011. DOI: 10.1016/j.ctrv.2010.07.006. PMID: 20724077.

A.J. Wigg, K. Palumbo, D.R. Wigg. Radiotherapy for hepatocellular carcinoma: systematic review of radiobiology and modeling projections indicate reconsideration of its use. „J Gastroenterol Hepatol”. 25 (4), s. 664–671, Apr 2010. DOI: 10.1111/j.1440-1746.2009.06126.x. PMID: 20074152.

J. Klein, L.A. Dawson. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. „Int J Radiat Oncol Biol Phys”. 87 (1), s. 22–32, Sep 2013. DOI: 10.1016/j.ijrobp.2012.08.043. PMID: 23219567.

M.A. Hawkins, L.A. Dawson. Radiation therapy for hepatocellular carcinoma: from palliation to cure. „Cancer”. 106 (8), s. 1653–1663, Apr 2006. DOI: 10.1002/cncr.21811. PMID: 16541431.

T. Kaizu, K. Karasawa, Y. Tanaka, T. Matuda i inni. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. „Am J Gastroenterol”. 93 (11), s. 2167–2171, Nov 1998. DOI: 10.1111/j.1572-0241.1998.00614.x. PMID: 9820391.

W. Jiang, Z.C. Zeng, J.Y. Zhang, J. Fan i inni. Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma. „Clin Exp Metastasis”. 29 (3), s. 197–205, Mar 2012. DOI: 10.1007/s10585-011-9442-4. PMID: 22173728.

J.L. Raoul, D. Guyader, J.F. Bretagne, J.F. Heautot i inni. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. „Hepatology”. 26 (5), s. 1156–1161, Nov 1997. DOI: 10.1002/hep.510260511. PMID: 9362356.

R. Salem, R.J. Lewandowski, M.F. Mulcahy, A. Riaz i inni. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. „Gastroenterology”. 138 (1), s. 52–64, Jan 2010. DOI: 10.1053/j.gastro.2009.09.006. PMID: 19766639.

M. Iñarrairaegui, K.G. Thurston, J.I. Bilbao, D. D’Avola i inni. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. „J Vasc Interv Radiol”. 21 (8), s. 1205–1212, Aug 2010. DOI: 10.1016/j.jvir.2010.04.012. PMID: 20598574.

L.M. Kulik, B.I. Carr, M.F. Mulcahy, R.J. Lewandowski i inni. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. „Hepatology”. 47 (1), s. 71–81, Jan 2008. DOI: 10.1002/hep.21980. PMID: 18027884.

B. Sangro, M. Iñarrairaegui, J.I. Bilbao. Radioembolization for hepatocellular carcinoma. „J Hepatol”. 56 (2), s. 464–473, Feb 2012. DOI: 10.1016/j.jhep.2011.07.012. PMID: 21816126.

B. Sangro, D. D’Avola, M. Iñarrairaegui, J. Prieto. Transarterial therapies for hepatocellular carcinoma. „Expert Opin Pharmacother”. 12 (7), s. 1057–1073, May 2011. DOI: 10.1517/14656566.2011.545346. PMID: 21470073.

B. Sangro, J.I. Bilbao, M. Iñarrairaegui, M. Rodriguez i inni. Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres. „Dig Dis”. 27 (2), s. 164–169, 2009. DOI: 10.1159/000218349. PMID: 19546555.

I.O. Ng, C.L. Liu, S.T. Fan, M. Ng. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. „Am J Clin Pathol”. 113 (3), s. 355–363, Mar 2000. DOI: 10.1309/AC1M-4TY4-U0TN-EN7T. PMID: 10705815.

J. Taieb, J.C. Barbare, P. Rougier. Medical treatments for hepatocellular carcinoma (HCC): what’s next?. „Ann Oncol”. 17 Suppl 10, s. x308-14, Sep 2006. DOI: 10.1093/annonc/mdl279. PMID: 17018744.

W. Yeo, T.S. Mok, B. Zee, T.W. Leung i inni. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. „J Natl Cancer Inst”. 97 (20), s. 1532–1538, Oct 2005. DOI: 10.1093/jnci/dji315. PMID: 16234567.

J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard i inni. Sorafenib in advanced hepatocellular carcinoma. „N Engl J Med”. 359 (4), s. 378–390, Jul 2008. DOI: 10.1056/NEJMoa0708857. PMID: 18650514.

S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie i inni. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. „Cancer Res”. 64 (19), s. 7099–7109, 2004. DOI: 10.1158/0008-5472.CAN-04-1443. PMID: 15466206.

S.A. Aziz, J.A. Sznol, L. Albiges, C. Zito i inni. Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. „Cancer Cell Int”. 14 (1), s. 4, 2014. DOI: 10.1186/1475-2867-14-4. PMID: 24423208.

A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao i inni. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. „Lancet Oncol”. 10 (1), s. 25–34, Jan 2009. DOI: 10.1016/S1470-2045(08)70285-7. PMID: 19095497.

J.F. Dufour, H. Hoppe, M.H. Heim, B. Helbling i inni. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. „Oncologist”. 15 (11), s. 1198–1204, 2010. DOI: 10.1634/theoncologist.2010-0180. PMID: 21036880.

A.B. Siegel, E.I. Cohen, A. Ocean, D. Lehrer i inni. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. „J Clin Oncol”. 26 (18), s. 2992–2998, Jun 2008. DOI: 10.1200/JCO.2007.15.9947. PMID: 18565886.

A.X. Zhu, L.S. Blaszkowsky, D.P. Ryan, J.W. Clark i inni. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. „J Clin Oncol”. 24 (12), s. 1898–1903, Apr 2006. DOI: 10.1200/JCO.2005.04.9130. PMID: 16622265.

Z. Mihály, Z. Sztupinszki, P. Surowiak, B. Győrffy. A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma. „Curr Cancer Drug Targets”, 2012-09. DOI: 10.2174/156800912802429265.

S. Faivre, E. Raymond, E. Boucher, J. Douillard i inni. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. „Lancet Oncol”. 10 (8), s. 794–800, Aug 2009. DOI: 10.1016/S1470-2045(09)70171-8. PMID: 19586800.

A.X. Zhu, D.V. Sahani, D.G. Duda, E. di Tomaso i inni. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. „J Clin Oncol”. 27 (18), s. 3027–3035, Jun 2009. DOI: 10.1200/JCO.2008.20.9908. PMID: 19470923.

D. Koeberle, M. Montemurro, P. Samaras, P. Majno i inni. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). „Oncologist”. 15 (3), s. 285–292, 2010. DOI: 10.1634/theoncologist.2009-0316. PMID: 20203173.

A.X. Zhu, M. Kudo, E. Assenat, S. Cattan i inni. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. „JAMA”. 312 (1), s. 57–67, Jul 2014. DOI: 10.1001/jama.2014.7189. PMID: 25058218.

P.A. Philip, M.R. Mahoney, C. Allmer, J. Thomas i inni. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. „J Clin Oncol”. 23 (27), s. 6657–6663, Sep 2005. DOI: 10.1200/JCO.2005.14.696. PMID: 16170173.

T. Bekaii-Saab, J. Markowitz, N. Prescott, W. Sadee i inni. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. „Clin Cancer Res”. 15 (18), s. 5895–5901, Sep 2009. DOI: 10.1158/1078-0432.CCR-09-0465. PMID: 19737952.

A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. „Hepatology”. 28 (3), s. 751–755, Sep 1998. DOI: 10.1002/hep.510280322. PMID: 9731568.

S. Kitai, M. Kudo, Y. Minami, S. Haji i inni. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. „Oncology”. 75 Suppl 1, s. 83–90, 2008. DOI: 10.1159/000173428. PMID: 19092276.

J.A. Marrero, R.J. Fontana, A. Barrat, F. Askari i inni. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. „Hepatology”. 41 (4), s. 707–716, Apr 2005. DOI: 10.1002/hep.20636. PMID: 15795889.

A. Guglielmi, A. Ruzzenente, S. Pachera, A. Valdegamberi i inni. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. „Am J Gastroenterol”. 103 (3), s. 597–604, Mar 2008. DOI: 10.1111/j.1572-0241.2007.01604.x. PMID: 17970836.

T. Takayama, M. Makuuchi, S. Hirohashi, M. Sakamoto i inni. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. „Hepatology”. 28 (5), s. 1241–1246, Nov 1998. DOI: 10.1002/hep.510280511. PMID: 9794907.

S. Arii, Y. Yamaoka, S. Futagawa, K. Inoue i inni. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. „Hepatology”. 32 (6), s. 1224–1229, Dec 2000. DOI: 10.1053/jhep.2000.20456. PMID: 11093728.

M. Burrel, M. Reig, A. Forner, M. Barrufet i inni. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. „J Hepatol”. 56 (6), s. 1330–1335, Jun 2012. DOI: 10.1016/j.jhep.2012.01.008. PMID: 22314428.

K. Takayasu, S. Arii, I. Ikai, M. Omata i inni. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. „Gastroenterology”. 131 (2), s. 461–469, Aug 2006. DOI: 10.1053/j.gastro.2006.05.021. PMID: 16890600.

nih.gov

ncbi.nlm.nih.gov

A. Reuben, R.P. Beasley. The crab, the turkey and a malignant tale from the year of the rooster. „Hepatology”. 41 (4), s. 944–950, Apr 2005. DOI: 10.1002/hep.20674. PMID: 15791605.

D.Y. But, C.L. Lai, M.F. Yuen. Natural history of hepatitis-related hepatocellular carcinoma. „World J Gastroenterol”. 14 (11), s. 1652–1656, Mar 2008. PMID: 18350595.

A.J. OHIN. Primary hepatic cancer among Africans and American Negroes. A comparative study, with a brief review of the literature on carcinoma of the liver. „Arch Surg”. 83, s. 667–673, Nov 1961. PMID: 14481362.

S.C. Cunningham, M.A. Choti, E.C. Bellavance, T.M. Pawlik. Palliation of hepatic tumors. „Surg Oncol”. 16 (4), s. 277–291, Dec 2007. DOI: 10.1016/j.suronc.2007.08.010. PMID: 17935975.

René G Holzheimer, John A Mannick: Surgical Treatment Evidence-Based and Problem-Oriented. Munich: Zuckschwerdt, 2001. ISBN 3-88603-714-2.

Y.S. Guan, Q. He, M.Q. Wang. Transcatheter arterial chemoembolization: history for more than 30 years. „ISRN Gastroenterol”. 2012, s. 480650, 2012. DOI: 10.5402/2012/480650. PMID: 22966466.

M.A. Friedman, P.A. Volberding, M.J. Cassidy, K.J. Resser i inni. Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: a Northern California Oncology Group Study. „Cancer Treat Rep”. 63 (11–12). s. 1885–1888. PMID: 230895.

N.C. Misra, M.S. Jaiswal, R.V. Singh, B. Das. Intrahepatic arterial infusion of combination of mitomycin-C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma. „Cancer”. 39 (4), s. 1425–1429, Apr 1977. PMID: 192431.

S. Rossi, F. Fornari, C. Pathies, L. Buscarini. Thermal lesions induced by 480 KHz localized current field in guinea pig and pig liver. „Tumori”. 76 (1), s. 54–57, Feb 1990. PMID: 2181746.

J.P. McGahan, P.D. Browning, J.M. Brock, H. Tesluk. Hepatic ablation using radiofrequency electrocautery. „Invest Radiol”. 25 (3), s. 267–270, Mar 1990. PMID: 2185179.

J.M. Llovet, J. Bruix. Novel advancements in the management of hepatocellular carcinoma in 2008. „J Hepatol”. 48 Suppl 1, s. S20-37, 2008. DOI: 10.1016/j.jhep.2008.01.022. PMID: 18304676.

H.B. El-Serag. Hepatocellular carcinoma. „N Engl J Med”. 365 (12), s. 1118–1127, Sep 2011. DOI: 10.1056/NEJMra1001683. PMID: 21992124.

F.X. Bosch, J. Ribes, M. Díaz, R. Cléries. Primary liver cancer: worldwide incidence and trends. „Gastroenterology”. 127 (5 Suppl 1), s. S5-S16, Nov 2004. PMID: 15508102.

J.M. Llovet, A. Burroughs, J. Bruix. Hepatocellular carcinoma. „Lancet”. 362 (9399), s. 1907–1917, Dec 2003. DOI: 10.1016/S0140-6736(03)14964-1. PMID: 14667750.

H.B. El-Serag. Hepatocellular carcinoma: an epidemiologic view. „J Clin Gastroenterol”. 35 (5 Suppl 2). s. S72-8. PMID: 12394209.

G. Fattovich, T. Stroffolini, I. Zagni, F. Donato. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. „Gastroenterology”. 127 (5 Suppl 1), s. S35-50, Nov 2004. PMID: 15508101.

F. Stickel, D. Schuppan, E.G. Hahn, H.K. Seitz. Cocarcinogenic effects of alcohol in hepatocarcinogenesis. „Gut”. 51 (1), s. 132–139, Jul 2002. PMID: 12077107.

H. Oka, N. Kurioka, K. Kim, T. Kanno i inni. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. „Hepatology”. 12 (4 Pt 1), s. 680–687, Oct 1990. PMID: 1698703.

M. Okuda, K. Li, M.R. Beard, L.A. Showalter i inni. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. „Gastroenterology”. 122 (2), s. 366–375, Feb 2002. PMID: 11832451.

K. Matsuzaki. Modulation of TGF-beta signaling during progression of chronic liver diseases. „Front Biosci (Landmark Ed)”. 14, s. 2923–2934, 2009. PMID: 19273245.

S.W. Jeong, J.Y. Jang, R.T. Chung. Hepatitis C virus and hepatocarcinogenesis. „Clin Mol Hepatol”. 18 (4), s. 347–356, Dec 2012. DOI: 10.3350/cmh.2012.18.4.347. PMID: 23323249.

Q. Zhou, V.W. Lui, W. Yeo. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. „Future Oncol”. 7 (10), s. 1149–1167, Oct 2011. DOI: 10.2217/fon.11.95. PMID: 21992728.

A. Satyanarayana, M.P. Manns, K.L. Rudolph. Telomeres and telomerase: a dual role in hepatocarcinogenesis. „Hepatology”. 40 (2), s. 276–283, Aug 2004. DOI: 10.1002/hep.20308. PMID: 15368430.

S.L. Friedman. Mechanisms of hepatic fibrogenesis. „Gastroenterology”. 134 (6), s. 1655–1669, May 2008. DOI: 10.1053/j.gastro.2008.03.003. PMID: 18471545.

K. Ohkubo, Y. Kato, T. Ichikawa, Y. Kajiya i inni. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. „Cancer”. 94 (10), s. 2663–2668, May 2002. PMID: 12173334.

M.C. Kew, R.H. Miller, H.S. Chen, B.C. Tennant i inni. Mutant woodchuck hepatitis virus genomes from virions resemble rearranged hepadnaviral integrants in hepatocellular carcinoma. „Proc Natl Acad Sci U S A”. 90 (21), s. 10211–10215, Nov 1993. PMID: 8234278.

H.B. El-Serag. Hepatocellular carcinoma and hepatitis C in the United States. „Hepatology”. 36 (5 Suppl 1), s. S74-83, Nov 2002. DOI: 10.1053/jhep.2002.36807. PMID: 12407579.

A. Sangiovanni, E. Del Ninno, P. Fasani, C. De Fazio i inni. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. „Gastroenterology”. 126 (4), s. 1005–1014, Apr 2004. PMID: 15057740.

T. Takayama, M. Makuuchi, S. Hirohashi, M. Sakamoto i inni. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. „Lancet”. 336 (8724), s. 1150–1153, Nov 1990. PMID: 1978027.

T.Y. Leong, A.S. Leong. Epidemiology and carcinogenesis of hepatocellular carcinoma. „HPB (Oxford)”. 7 (1), s. 5–15, 2005. DOI: 10.1080/13651820410024021. PMID: 18333156.

K. Koike. The oncogenic role of hepatitis C virus. „Recent Results Cancer Res”. 193, s. 97–111, 2014. DOI: 10.1007/978-3-642-38965-8_6. PMID: 24008295.

R.B. Ray, R. Steele, K. Meyer, R. Ray. Transcriptional repression of p53 promoter by hepatitis C virus core protein. „J Biol Chem”. 272 (17), s. 10983–10986, Apr 1997. PMID: 9110985.

J. Cho, W. Baek, S. Yang, J. Chang i inni. HCV core protein modulates Rb pathway through pRb down-regulation and E2F-1 up-regulation. „Biochim Biophys Acta”. 1538 (1), s. 59–66, Feb 2001. PMID: 11341983.

H.J. Kwun, K.L. Jang. Dual effects of hepatitis C virus Core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene. „J Viral Hepat”. 10 (4), s. 249–255, Jul 2003. PMID: 12823590.

M. Levrero. Viral hepatitis and liver cancer: the case of hepatitis C. „Oncogene”. 25 (27), s. 3834–3847, Jun 2006. DOI: 10.1038/sj.onc.1209562. PMID: 16799625.

W.L. Tsai, R.T. Chung. Viral hepatocarcinogenesis. „Oncogene”. 29 (16), s. 2309–2324, Apr 2010. DOI: 10.1038/onc.2010.36. PMID: 20228847.

H. Kuper, A. Tzonou, E. Kaklamani, C.C. Hsieh i inni. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. „Int J Cancer”. 85 (4), s. 498–502, Feb 2000. PMID: 10699921.

M.J. Hill, G.J. Davies, A. Giacosa. Should we change our dietary advice on cancer prevention?. „Eur J Cancer Prev”. 10 (1), s. 1–6, Feb 2001. PMID: 11263581.

G. Pöschl, H.K. Seitz. Alcohol and cancer. „Alcohol Alcohol”. 39 (3), s. 155–165, 2004. PMID: 15082451.

H. Inoue, H.K. Seitz. Viruses and alcohol in the pathogenesis of primary hepatic carcinoma. „Eur J Cancer Prev”. 10 (1), s. 107–110, Feb 2001. PMID: 11263585.

T.R. Morgan, S. Mandayam, M.M. Jamal. Alcohol and hepatocellular carcinoma. „Gastroenterology”. 127 (5 Suppl 1), s. S87-96, Nov 2004. PMID: 15508108.

M.B. Thomas, A.X. Zhu. Hepatocellular carcinoma: the need for progress. „J Clin Oncol”. 23 (13), s. 2892–2899, May 2005. DOI: 10.1200/JCO.2005.03.196. PMID: 15860847.

P. Prior. Long-term cancer risk in alcoholism. „Alcohol Alcohol”. 23 (2), s. 163–171, 1988. PMID: 3390240.

F. Donato, A. Tagger, U. Gelatti, G. Parrinello i inni. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. „Am J Epidemiol”. 155 (4), s. 323–331, Feb 2002. PMID: 11836196.

T.I. Sørensen. Alcohol and liver injury: dose-related or permissive effect?. „Liver”. 9 (4), s. 189–197, Aug 1989. PMID: 2671569.

M. Yamauchi, M. Nakahara, Y. Maezawa, S. Satoh i inni. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. „Am J Gastroenterol”. 88 (1), s. 39–43, Jan 1993. PMID: 7678368.

G. Corrao, F. Carle, A.R. Lepore, E. Zepponi i inni. Interaction between alcohol consumption and positivity for antibodies to hepatitis C virus on the risk of liver cirrhosis: a case-control study. Provincial Group for the Study of Chronic Liver Disease. „Eur J Epidemiol”. 8 (5), s. 634–639, Sep 1992. PMID: 1330673.

K.G. Tolman, A.S. Dalpiaz. Treatment of non-alcoholic fatty liver disease. „Ther Clin Risk Manag”. 3 (6), s. 1153–1163, Dec 2007. PMID: 18516264.

E. Bugianesi, N. Leone, E. Vanni, G. Marchesini i inni. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. „Gastroenterology”. 123 (1), s. 134–140, Jul 2002. PMID: 12105842.

L. Kikuchi, C.P. Oliveira, F.J. Carrilho. Nonalcoholic fatty liver disease and hepatocellular carcinoma. „Biomed Res Int”. 2014, s. 106247, 2014. DOI: 10.1155/2014/106247. PMID: 24738043.

S.H. Caldwell, D.M. Crespo, H.S. Kang, A.M. Al-Osaimi. Obesity and hepatocellular carcinoma. „Gastroenterology”. 127 (5 Suppl 1), s. S97-103, Nov 2004. PMID: 15508109.

W. Hu, Z. Feng, J. Eveleigh, G. Iyer i inni. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. „Carcinogenesis”. 23 (11), s. 1781–1789, Nov 2002. PMID: 12419825.

H.B. El-Serag, T. Tran, J.E. Everhart. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. „Gastroenterology”. 126 (2), s. 460–468, Feb 2004. PMID: 14762783.

M.C. Kew. Aflatoxins as a cause of hepatocellular carcinoma. „J Gastrointestin Liver Dis”. 22 (3), s. 305–310, Sep 2013. PMID: 24078988.

E.A. Bailey, R.S. Iyer, M.P. Stone, T.M. Harris i inni. Mutational properties of the primary aflatoxin B1-DNA adduct. „Proc Natl Acad Sci U S A”. 93 (4), s. 1535–1539, Feb 1996. PMID: 8643667.

C.P. Wild, P.C. Turner. The toxicology of aflatoxins as a basis for public health decisions. „Mutagenesis”. 17 (6), s. 471–481, Nov 2002. PMID: 12435844.

A. Magnussen, M.A. Parsi. Aflatoxins, hepatocellular carcinoma and public health. „World J Gastroenterol”. 19 (10), s. 1508–1512, Mar 2013. DOI: 10.3748/wjg.v19.i10.1508. PMID: 23539499.

H.C. Wu, R. Santella. The role of aflatoxins in hepatocellular carcinoma. „Hepat Mon”. 12 (10 HCC), s. e7238, Oct 2012. DOI: 10.5812/hepatmon.7238. PMID: 23162603.

C.P. Wild, Y.Y. Gong. Mycotoxins and human disease: a largely ignored global health issue. „Carcinogenesis”. 31 (1), s. 71–82, Jan 2010. DOI: 10.1093/carcin/bgp264. PMID: 19875698.

G. Strohmeyer, C. Niederau, W. Stremmel. Survival and causes of death in hemochromatosis. Observations in 163 patients. „Ann N Y Acad Sci”. 526, s. 245–257, 1988. PMID: 3389643.

R.A. Bradbear, C. Bain, V. Siskind, F.D. Schofield i inni. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. „J Natl Cancer Inst”. 75 (1), s. 81–84, Jul 1985. PMID: 2989605.

M.C. Kew. Hepatic iron overload and hepatocellular carcinoma. „Liver Cancer”. 3 (1), s. 31–40, Mar 2014. DOI: 10.1159/000343856. PMID: 24804175.

T.A. Dragani. Risk of HCC: genetic heterogeneity and complex genetics. „J Hepatol”. 52 (2), s. 252–257, Feb 2010. DOI: 10.1016/j.jhep.2009.11.015. PMID: 20022654.

A.N. Elzouki, S. Eriksson. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma?. „Eur J Gastroenterol Hepatol”. 8 (10), s. 989–994, Oct 1996. PMID: 8930564.

C.R. Scott. The genetic tyrosinemias. „Am J Med Genet C Semin Med Genet”. 142C (2), s. 121–126, May 2006. DOI: 10.1002/ajmg.c.30092. PMID: 16602095.

A.G. Weinberg, C.E. Mize, H.G. Worthen. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. „J Pediatr”. 88 (3), s. 434–438, Mar 1976. PMID: 173827.

C. Andant, H. Puy, C. Bogard, J. Faivre i inni. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. „J Hepatol”. 32 (6), s. 933–939, Jun 2000. PMID: 10898313.

H. Salata, J.M. Cortés, R. Enríquez de Salamanca, H. Oliva i inni. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. „J Hepatol”. 1 (5), s. 477–487, 1985. PMID: 2997323.

P.J. Lee. Glycogen storage disease type I: pathophysiology of liver adenomas. „Eur J Pediatr”. 161 Suppl 1, s. S46-9, Oct 2002. DOI: 10.1007/s00431-002-1002-0. PMID: 12373570.

L. Bianchi. Glycogen storage disease I and hepatocellular tumours. „Eur J Pediatr”. 152 Suppl 1, s. S63-70, 1993. PMID: 8391447.

R. Xu, C.H. Hajdu. Wilson disease and hepatocellular carcinoma. „Gastroenterol Hepatol (N Y)”. 4 (6), s. 438–439, Jun 2008. PMID: 21904522.

L. Rosenberg. The risk of liver neoplasia in relation to combined oral contraceptive use. „Contraception”. 43 (6), s. 643–652, Jun 1991. PMID: 1651205.

M.A. Hamed, S.A. Ali. Non-viral factors contributing to hepatocellular carcinoma. „World J Hepatol”. 5 (6), s. 311–322, Jun 2013. DOI: 10.4254/wjh.v5.i6.311. PMID: 23805355.

J. Korula, A. Yellin, G. Kanel, G. Campofiori i inni. Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. „West J Med”. 155 (4), s. 416–418, Oct 1991. PMID: 1663298.

Y.H. Chou, H.J. Chiou, C.M. Tiu, S.Y. Chiou i inni. Duplex Doppler ultrasound of hepatic Schistosomiasis japonica: a study of 47 patients. „Am J Trop Med Hyg”. 68 (1), s. 18–23, Jan 2003. PMID: 12556142.

S. Ezzat, M. Abdel-Hamid, S.A. Eissa, N. Mokhtar i inni. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. „Int J Hyg Environ Health”. 208 (5), s. 329–339, 2005. PMID: 16217918.

T. Mizoue, N. Tokui, K. Nishisaka, S. Nishisaka i inni. Prospective study on the relation of cigarette smoking with cancer of the liver and stomach in an endemic region. „Int J Epidemiol”. 29 (2), s. 232–237, Apr 2000. PMID: 10817118.

A.A. Evans, G. Chen, E.A. Ross, F.M. Shen i inni. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. „Cancer Epidemiol Biomarkers Prev”. 11 (4), s. 369–376, Apr 2002. PMID: 11927497.

C.A. Sun, D.M. Wu, C.C. Lin, S.N. Lu i inni. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. „Am J Epidemiol”. 157 (8), s. 674–682, Apr 2003. PMID: 12697571.

A. Teufel, A. Weinmann, C. Centner, A. Piendl i inni. Hepatocellular carcinoma in patients with autoimmune hepatitis. „World J Gastroenterol”. 15 (5), s. 578–582, Feb 2009. PMID: 19195059.

J. Meza-Junco, A.J. Montaño-Loza, B. Martínez-Benitez, E. Kimura-Hayama. Hepatocellular carcinoma in patients with autoimmune liver diseases: two case reports and literature review. „Ann Hepatol”. 6 (2). s. 122–126. PMID: 17519838.

The Adult Hepatitis Vaccine Project – California, 2007–2008. „MMWR Morb Mortal Wkly Rep”. 59 (17), s. 514–516, May 2010. PMID: 20448527.

A.M. Di Bisceglie. Epidemiology and clinical presentation of hepatocellular carcinoma. „J Vasc Interv Radiol”. 13 (9 Pt 2), s. S169-71, Sep 2002. PMID: 12354833.

M.H. Chang. Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. „Liver Int”. 23 (5), s. 309–314, Oct 2003. PMID: 14708890.

M.C. Kew. Prevention of hepatocellular carcinoma. „HPB (Oxford)”. 7 (1), s. 16–25, 2005. DOI: 10.1080/13651820410024030. PMID: 18333157.

M. Stepień, M.P. Czarkowski. [Hepatitis B in Poland in 2010]. „Przegl Epidemiol”. 66 (2), s. 277–285, 2012. PMID: 23101217.

D.B. Brettler, P.M. Mannucci, A. Gringeri, J.E. Rasko i inni. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. „Blood”. 80 (2), s. 540–543, Jul 1992. PMID: 1627805.

J.G. Feldman, H. Minkoff, S. Landesman, J. Dehovitz. Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner city women. „Sex Transm Dis”. 27 (6), s. 338–342, Jul 2000. PMID: 10907909.

Q. Qu, S. Wang, S. Chen, L. Zhou i inni. Prognostic role and significance of paraneoplastic syndromes in hepatocellular carcinoma. „Am Surg”. 80 (2), s. 191–196, Feb 2014. PMID: 24480222.

R.B. Goldberg, I. Bersohn, M.C. Kew. Hypercholesterolaemia in primary cancer of the liver. „S Afr Med J”. 49 (36), s. 1464–1466, Aug 1975. PMID: 169598.

M.W. Ghobrial, J. George, S. Mannam, S.R. Henien. Severe hypercalcemia as an initial presenting manifestation of hepatocellular carcinoma. „Can J Gastroenterol”. 16 (9), s. 607–609, Sep 2002. PMID: 12362213.

S. Sultan-e-Rome, A.A. Sharif, Shah. Parathryoid hormone related peptide causing hypercalcaemia in a patient with hepatocellular carcinoma. „J Pak Med Assoc”. 63 (2), s. 263–264, Feb 2013. PMID: 23894909.

M.R. Arguedas, B.M. McGuire. Hepatocellular carcinoma presenting with chronic inflammatory demyelinating polyradiculoneuropathy. „Dig Dis Sci”. 45 (12), s. 2369–2373, Dec 2000. PMID: 11258560.

J. Walcher, T. Witter, H.D. Rupprecht. Hepatocellular carcinoma presenting with paraneoplastic demyelinating polyneuropathy and PR3-antineutrophil cytoplasmic antibody. „J Clin Gastroenterol”. 35 (4), s. 364–365, Oct 2002. PMID: 12352308.

K. Abe, F. Sugai. Chronic inflammatory demyelinating polyneuropathy accompanied by carcinoma. „J Neurol Neurosurg Psychiatry”. 65 (3), s. 403–404, Sep 1998. PMID: 9728965.

F. Sugai, K. Abe, T. Fujimoto, S. Nagano i inni. Chronic inflammatory demyelinating polyneuropathy accompanied by hepatocellular carcinoma. „Intern Med”. 36 (1), s. 53–55, Jan 1997. PMID: 9058102.

A. Coeytaux, R. Kressig, G.B. Zulian. Hepatocarcinoma with concomitant paraneoplastic encephalomyelitis. „J Palliat Care”. 17 (1), s. 59–60, 2001. PMID: 11324188.

G. Hinterhuber, J. Drach, E. Riedl, K. Böhler i inni. Paraneoplastic pemphigus in association with hepatocellular carcinoma. „J Am Acad Dermatol”. 49 (3), s. 538–540, Sep 2003. PMID: 12963927.

M.J. Kim, J.A. Kim, M.S. Sung, J.K. Min. Hepatocellular carcinoma, polymyositis, rhabdomyolysis, and acute renal failure. „J Korean Med Sci”. 19 (6), s. 891–894, Dec 2004. PMID: 15608404.

K. Hasegawa, H. Uesugi, K. Kubota, Y. Ugawa i inni. Polymyositis as a paraneoplastic manifestation of hepatocellular carcinoma. „Hepatogastroenterology”. 47 (35). s. 1425–1427. PMID: 11100367.

K.M. Kee, J.H. Wang, C.M. Lee, C.S. Changchien i inni. Chronic hepatitis C virus infection associated with dermatomyositis and hepatocellular carcinoma. „Chang Gung Med J”. 27 (11), s. 834–839, Nov 2004. PMID: 15796260.

N. Toshikuni, R. Torigoe, M. Mitsunaga, A. Omoto i inni. Dermatomyositis associated with hepatocellular carcinoma in an elderly female patient with hepatitis C virus-related liver cirrhosis. „World J Gastroenterol”. 12 (10), s. 1641–1644, Mar 2006. PMID: 16570363.

S. Glinkov, I. Krasnaliev, M. Atanassova, P. Arnaudov i inni. Hepatocellular carcinoma associated with paraneoplastic erythema nodosum and polyarthritis. „J Hepatol”. 39 (4), s. 656–657, Oct 2003. PMID: 12971982.

S.J. Hwang, J.C. Luo, C.P. Li, C.W. Chu i inni. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. „World J Gastroenterol”. 10 (17), s. 2472–2477, Sep 2004. PMID: 15300887.

M. Inuzuka, K. Tomita, Y. Tokura, M. Takigawa. Acquired ichthyosis associated with dermatomyositis in a patient with hepatocellular carcinoma. „Br J Dermatol”. 144 (2), s. 416–417, Feb 2001. PMID: 11251586.

P.Y. Lo, T.Y. Tzung. Lichen myxedematosus in a patient with hepatocellular carcinoma. „Br J Dermatol”. 143 (2), s. 452–453, Aug 2000. PMID: 10951167.

M. Sökmen, H. Demirsoy, O. Ersoy, G. Gökdemir i inni. Paraneoplastic porphyria cutanea tarda associated with cholangiocarcinoma: case report. „Turk J Gastroenterol”. 18 (3), s. 200–205, Sep 2007. PMID: 17891697.

W.S. Huang, L.Y. Liao, C.S. Wang, P.H. Chen. Hepatocellular carcinoma presenting with acquired porphyria: a case report and review of the literature. „Changgeng Yi Xue Za Zhi”. 22 (1), s. 111–116, Mar 1999. PMID: 10418219.

T. Ochiai, T. Morishima, M. Kondo. Symptomatic porphyria secondary to hepatocellular carcinoma. „Br J Dermatol”. 136 (1), s. 129–131, Jan 1997. PMID: 9039312.

G. Kamińska-Winciorek, L. Brzezińska-Wcisło, A. Lis-Swiety, E. Krauze. Paraneoplastic type of acanthosis nigricans in patient with hepatocellular carcinoma. „Adv Med Sci”. 52, s. 254–256, 2007. PMID: 18217428.

J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand i inni. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. „J Hepatol”. 35 (3), s. 421–430, Sep 2001. PMID: 11592607.

M. Colombo. Natural history of hepatocellular carcinoma. „Ann Ital Chir”. 79 (2). s. 91–97. PMID: 18727270.

N. Okazaki, M. Yoshino, T. Yoshida, M. Suzuki i inni. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. „Cancer”. 63 (11), s. 2207–2210, Jun 1989. PMID: 2541886.

M. Cottone, R. Virdone, G. Fusco, A. Orlando i inni. Asymptomatic hepatocellular carcinoma in Child’s A cirrhosis. A comparison of natural history and surgical treatment. „Gastroenterology”. 96 (6), s. 1566–1571, Jun 1989. PMID: 2469617.

J. Kaczynski, G. Hansson, S. Wallerstedt. Metastases in cases with hepatocellular carcinoma in relation to clinicopathologic features of the tumor. An autopsy study from a low endemic area. „Acta Oncol”. 34 (1), s. 43–48, 1995. PMID: 7865235.

K. Yuki, S. Hirohashi, M. Sakamoto, T. Kanai i inni. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. „Cancer”. 66 (10), s. 2174–2179, Nov 1990. PMID: 2171748.

J. Bruix, M. Sherman. Management of hepatocellular carcinoma. „Hepatology”. 42 (5), s. 1208–1236, Nov 2005. DOI: 10.1002/hep.20933. PMID: 16250051.

J. Bruix, M. Sherman. Management of hepatocellular carcinoma: an update. „Hepatology”. 53 (3), s. 1020–1022, Mar 2011. DOI: 10.1002/hep.24199. PMID: 21374666.

E.S. Bialecki, A.M. Di Bisceglie. Diagnosis of hepatocellular carcinoma. „HPB (Oxford)”. 7 (1), s. 26–34, 2005. DOI: 10.1080/13651820410024049. PMID: 18333158.

J. Yoshikawa, O. Matsui, M. Kadoya, T. Gabata i inni. Delayed enhancement of fibrotic areas in hepatic masses: CT-pathologic correlation. „J Comput Assist Tomogr”. 16 (2). s. 206–211. PMID: 1312098.

J. Ward, P.J. Robinson. How to detect hepatocellular carcinoma in cirrhosis. „Eur Radiol”. 12 (9), s. 2258–2272, Sep 2002. DOI: 10.1007/s00330-002-1450-y. PMID: 12195479.

S.D. Ryder. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. „Gut”. 52 Suppl 3, s. iii1-8, May 2003. PMID: 12692148.

B.I. Choi, A.Y. Kim, J.Y. Lee, K.W. Kim i inni. Hepatocellular carcinoma: contrast enhancement with Levovist. „J Ultrasound Med”. 21 (1), s. 77–84, Jan 2002. PMID: 11794406.

C.I. Dumitrescu, I.A. Gheonea, L. Săndulescu, V. Surlin i inni. Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. „Med Ultrason”. 15 (4), s. 261–267, Dec 2013. PMID: 24286088.

S. Liangpunsakul, D. Agarwal, J.C. Horlander, B. Kieff i inni. Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis C cirrhotics awaiting for liver transplantation. „Transplant Proc”. 35 (8), s. 2995–2997, Dec 2003. PMID: 14697959.

R. Dierckx, A. Maes, M. Peeters, C. Van De Wiele. FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. „Q J Nucl Med Mol Imaging”. 53 (3), s. 336–342, Jun 2009. PMID: 19521313.

Y. Iwata, S. Shiomi, N. Sasaki, H. Jomura i inni. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. „Ann Nucl Med”. 14 (2), s. 121–126, Apr 2000. PMID: 10830530.

M. Borzio, F. Borzio, R. Macchi, A.M. Croce i inni. The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis. „J Hepatol”. 20 (1), s. 117–121, Jan 1994. PMID: 8201212.

Y.J. Zhao, Q. Ju, G.C. Li. Tumor markers for hepatocellular carcinoma. „Mol Clin Oncol”. 1 (4), s. 593–598, Jul 2013. DOI: 10.3892/mco.2013.119. PMID: 24649215.

F. Trevisani, P.E. D’Intino, A.M. Morselli-Labate, G. Mazzella i inni. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. „J Hepatol”. 34 (4), s. 570–575, Apr 2001. PMID: 11394657.

P. Tangkijvanich, N. Anukulkarnkusol, P. Suwangool, S. Lertmaharit i inni. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. „J Clin Gastroenterol”. 31 (4), s. 302–308, Dec 2000. PMID: 11129271.

P.J. Johnson. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. „Clin Liver Dis”. 5 (1), s. 145–159, Feb 2001. PMID: 11218912.

B. Zhang, B. Yang. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. „J Med Screen”. 6 (2), s. 108–110, 1999. PMID: 10444731.

P. Tangkijvanich, P. Tosukhowong, P. Bunyongyod, S. Lertmaharit i inni. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. „Southeast Asian J Trop Med Public Health”. 30 (1), s. 110–114, Mar 1999. PMID: 10695798.

M. Joo, J.G. Chi, H. Lee. Expressions of HSP70 and HSP27 in hepatocellular carcinoma. „J Korean Med Sci”. 20 (5), s. 829–834, Oct 2005. PMID: 16224158.

J. Filmus, M. Capurro, J. Rast. Glypicans. „Genome Biol”. 9 (5), s. 224, 2008. DOI: 10.1186/gb-2008-9-5-224. PMID: 18505598.

F.R. Fritzsche, M.O. Riener, M. Dietel, H. Moch i inni. GOLPH2 expression in renal cell cancer. „BMC Urol”. 8, s. 15, 2008. DOI: 10.1186/1471-2490-8-15. PMID: 19014428.

Y. Shi, J. Chen, L. Li, Z. Sun i inni. A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. „Technol Cancer Res Treat”. 10 (3), s. 287–294, Jun 2011. PMID: 21517136.

Y.L. Mao, H.Y. Yang, H.F. Xu, X.T. Sang i inni. [Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study]. „Zhonghua Yi Xue Za Zhi”. 88 (14), s. 948–951, Apr 2008. PMID: 18756964.

V. Cartier, C. Aubé. Diagnosis of hepatocellular carcinoma. „Diagn Interv Imaging”. 95 (7–8). s. 709–719. DOI: 10.1016/j.diii.2014.06.004. PMID: 24997859.

S. Terasaki, S. Kaneko, K. Kobayashi, A. Nonomura i inni. Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study. „Gastroenterology”. 115 (5), s. 1216–1222, Nov 1998. PMID: 9797377.

M. Borzio, S. Fargion, F. Borzio, A.L. Fracanzani i inni. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. „J Hepatol”. 39 (2), s. 208–214, Aug 2003. PMID: 12873817.

J. Bruix, A. Castells, J. Bosch, F. Feu i inni. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. „Gastroenterology”. 111 (4), s. 1018–1022, Oct 1996. PMID: 8831597.

K.J. Simpson, N.D. Finlayson. Clinical evaluation of liver disease. „Baillieres Clin Gastroenterol”. 9 (4), s. 639–659, Dec 1995. PMID: 8903798.

M. Makuuchi, K. Sano. The surgical approach to HCC: our progress and results in Japan. „Liver Transpl”. 10 (2 Suppl 1), s. S46-52, Feb 2004. DOI: 10.1002/lt.20044. PMID: 14762839.

J. Belghiti, Y. Panis, O. Farges, J.P. Benhamou i inni. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. „Ann Surg”. 214 (2), s. 114–117, Aug 1991. PMID: 1714267.

E. Adachi, T. Maeda, T. Matsumata, K. Shirabe i inni. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. „Gastroenterology”. 108 (3), s. 768–775, Mar 1995. PMID: 7875479.

G.L. Grazi, G. Ercolani, F. Pierangeli, M. Del Gaudio i inni. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. „Ann Surg”. 234 (1), s. 71–78, Jul 2001. PMID: 11420485.

Y. Fong, R.L. Sun, W. Jarnagin, L.H. Blumgart. An analysis of 412 cases of hepatocellular carcinoma at a Western center. „Ann Surg”. 229 (6), s. 790-799; discussion 799-800, Jun 1999. PMID: 10363892.

A. Liccioni, M. Reig, J. Bruix. Treatment of hepatocellular carcinoma. „Dig Dis”. 32 (5), s. 554–563, 2014. DOI: 10.1159/000360501. PMID: 25034288.

S.A. Farkas, H.J. Schlitt. [Operative therapy of hepatocellular carcinoma]. „Radiologe”. 54 (7), s. 673–678, Jul 2014. DOI: 10.1007/s00117-014-2653-3. PMID: 25047523.

H. Bismuth, P.E. Majno, R. Adam. Liver transplantation for hepatocellular carcinoma. „Semin Liver Dis”. 19 (3), s. 311–322, 1999. DOI: 10.1055/s-2007-1007120. PMID: 10518310.

V. Mazzaferro, C. Battiston, S. Perrone, A. Pulvirenti i inni. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. „Ann Surg”. 240 (5), s. 900–909, Nov 2004. PMID: 15492574.

P.E. Majno, R. Adam, H. Bismuth, D. Castaing i inni. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. „Ann Surg”. 226 (6), s. 688-701; discussion 701-3, Dec 1997. PMID: 9409568.

J.M. Llovet, X. Mas, J.J. Aponte, J. Fuster i inni. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. „Gut”. 50 (1), s. 123–128, Jan 2002. PMID: 11772979.

J.W. Cheng, Y. Lv. New progress of non-surgical treatments for hepatocellular carcinoma. „Med Oncol”. 30 (1), s. 381, Mar 2013. DOI: 10.1007/s12032-012-0381-y. PMID: 23292867.

P.J. Johnson. Non-surgical treatment of hepatocellular carcinoma. „HPB (Oxford)”. 7 (1), s. 50–55, 2005. DOI: 10.1080/13651820410024076. PMID: 18333161.

R. Lencioni, L. Crocetti. Local-regional treatment of hepatocellular carcinoma. „Radiology”. 262 (1), s. 43–58, Jan 2012. DOI: 10.1148/radiol.11110144. PMID: 22190656.

K.N. Khan, H. Yatsuhashi, K. Yamasaki, M. Yamasaki i inni. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. „J Hepatol”. 32 (2), s. 269–278, Feb 2000. PMID: 10707867.

S. Shiina, T. Teratani, S. Obi, S. Sato i inni. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. „Gastroenterology”. 129 (1), s. 122–130, Jul 2005. PMID: 16012942.

S.M. Lin, C.J. Lin, C.C. Lin, C.W. Hsu i inni. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. „Gastroenterology”. 127 (6), s. 1714–1723, Dec 2004. PMID: 15578509.

B.I. Carr, A. Zajko, K. Bron, P. Orons i inni. Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis. „Semin Oncol”. 24 (2 Suppl 6), s. S6-97-S6-99, Apr 1997. PMID: 9151923.

Y. Teshima, N. Iwasaki. Efficacy of CO2-DSA in embolization. „Cancer Chemother Pharmacol”. 33 Suppl, s. S109-10, 1994. PMID: 8137467.

T. Gunji, N. Kawauchi, S. Ohnishi, T. Ishikawa i inni. Treatment of hepatocellular carcinoma associated with advanced cirrhosis by transcatheter arterial chemoembolization using autologous blood clot: a preliminary report. „Hepatology”. 15 (2), s. 252–257, Feb 1992. PMID: 1310476.

J. Bruix, M. Sala, J.M. Llovet. Chemoembolization for hepatocellular carcinoma. „Gastroenterology”. 127 (5 Suppl 1), s. S179-88, Nov 2004. PMID: 15508083.

M.A. Hawkins, L.A. Dawson. Radiation therapy for hepatocellular carcinoma: from palliation to cure. „Cancer”. 106 (8), s. 1653–1663, Apr 2006. DOI: 10.1002/cncr.21811. PMID: 16541431.

B. Sangro, M. Iñarrairaegui, J.I. Bilbao. Radioembolization for hepatocellular carcinoma. „J Hepatol”. 56 (2), s. 464–473, Feb 2012. DOI: 10.1016/j.jhep.2011.07.012. PMID: 21816126.

Y.Y. Chou, A.L. Cheng, H.C. Hsu. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. „J Gastroenterol Hepatol”. 12 (8), s. 569–575, Aug 1997. PMID: 9304508.

P.J. Johnson. Hepatocellular carcinoma: is current therapy really altering outcome?. „Gut”. 51 (4), s. 459–462, Oct 2002. PMID: 12235060.

Beevers, C, Li, F, Liu, L, Huang, S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. „Int J Cancer”. 119. 4, s. 757–764, 2006. PMID: 16550606.

S. Chevret, J.C. Trinchet, D. Mathieu, A.A. Rached i inni. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire. „J Hepatol”. 31 (1), s. 133–141, Jul 1999. PMID: 10424293.

T.W. Leung, A.M. Tang, B. Zee, W.Y. Lau i inni. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. „Cancer”. 94 (6), s. 1760–1769, Mar 2002. PMID: 11920539.

pzh.gov.pl

przeglepidemiol.pzh.gov.pl

Piotr Małkowski, Marek Pacholczyk, Beata Łągiewska, Leszek Adadyński, Dariusz Wasiak, Artur Kwiatkowski, Andrzej Chmura, Jarosław Czerwiński. Rak wątrobowokomórkowy – epidemiologia i leczenie. „Przegl. Epidemiol.”. 60 (4), 2006. [dostęp 2014-07-01]. [zarchiwizowane z adresu].

viamedica.pl

czasopisma.viamedica.pl

Maciej Krzakowski, Krzysztof Zieniewicz, Andrzej Habior, Andrzej Horban, Włodzimierz Olszewski, Janusz Cianciara, Krzysztof Simon, Marek Hartleb, Jarosław Reguła, Ryszard Pacho, Olgierd Rowiński, Bogna Ziarkiewicz-Wróblewska, Marek Krawczyk, Piotr Małkowski, Jacek Jassem. Rak wątrobowokomórkowy – rozpoznanie i leczenie. „Onkologia w Praktyce Klinicznej”, 2009. [dostęp 2014-06-29].

Edyta Szurowska, Tomasz Nowicki, Michał Studniarek. Diagnostyka obrazowa raka pierwotnego wątroby. „Onkologia w Praktyce Klinicznej”, 2011.

Rak wątrobowokomórkowy (Polish Wikipedia)

aacrjournals.org

cancerres.aacrjournals.org

alphamedpress.org

theoncologist.alphamedpress.org

archive.is

ascopubs.org

jco.ascopubs.org

cdc.gov

doi.org

easl.eu

google.pl

books.google.pl

indexcopernicus.com

960.indexcopernicus.com

journal-of-hepatology.eu

lww.com

journals.lww.com

medscape.com

nature.com

nejm.org

nih.gov

ncbi.nlm.nih.gov

pzh.gov.pl

przeglepidemiol.pzh.gov.pl

redjournal.org

viamedica.pl

czasopisma.viamedica.pl

web.archive.org

who.int

wiley.com

onlinelibrary.wiley.com